Pfizer Agrees To Let Other Companies Manufacture Its COVID-19 Pill

The video discusses a COVID-19 pill that could be available to over half the world's population. The pharmaceutical company will not charge royalties in low-income countries and will waive them where COVID-19 remains a public health emergency. The pill reportedly reduces hospitalization and death by 90% in mild and moderate cases. The company is awaiting federal authorization.

What is the potential global impact of the COVID-19 pill?

• It will not be available globally.

• It will be available to less than half the world population.

• It will be available to more than half the world population.

• It will only be available in high-income countries.

What is the policy regarding royalties for the COVID-19 pill in low-income countries?

• Royalties will be waived.

• Royalties will be reduced by 50%.

• Royalties will be doubled.

• Royalties will remain the same.

Under what condition will royalties be waived for the COVID-19 pill?

• When the pill is ineffective.

• When the pill is federally authorized.

• When the virus is still a public health emergency.

• When the virus is no longer a public health emergency.

By what percentage does the COVID-19 pill reduce hospitalization and death rates in mild and moderate cases?

• 50%

• 70%

• 90%

• 100%

What is the current status of the COVID-19 pill regarding federal authorization?

• It has been fully authorized.

• It is still waiting on federal authorization.

• It has been rejected.

• It is authorized only in some states.